These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 29039073

  • 1. A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy.
    Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K, Nakao M, Sakai H, Nakayama T, Minato K, Arai T, Suzuki K, Shimada Y, Nagashima K, Terakado H, Yamamoto N.
    Int J Clin Oncol; 2018 Apr; 23(2):382-388. PubMed ID: 29039073
    [Abstract] [Full Text] [Related]

  • 2. A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.
    Nakashima K, Murakami H, Yokoyama K, Omori S, Wakuda K, Ono A, Kenmotsu H, Naito T, Nishiyama F, Kikugawa M, Kaneko M, Iwamoto Y, Koizumi S, Mori K, Isobe T, Takahashi T.
    Jpn J Clin Oncol; 2017 Sep 01; 47(9):840-843. PubMed ID: 28633504
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
    Abe M, Hirashima Y, Kasamatsu Y, Kado N, Komeda S, Kuji S, Tanaka A, Takahashi N, Takekuma M, Hihara H, Ichikawa Y, Itonaga Y, Hirakawa T, Nasu K, Miyagi K, Murakami J, Ito K.
    Support Care Cancer; 2016 Feb 01; 24(2):675-682. PubMed ID: 26130365
    [Abstract] [Full Text] [Related]

  • 4. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
    Navari RM, Nagy CK, Gray SE.
    Support Care Cancer; 2013 Jun 01; 21(6):1655-63. PubMed ID: 23314603
    [Abstract] [Full Text] [Related]

  • 5. A phase II trial of prophylactic olanzapine combined with palonosetron and dexamethasone for preventing nausea and vomiting induced by cisplatin.
    Maeda A, Ura T, Asano C, Haegawa I, Nomura M, Komori A, Narita Y, Taniguchi H, Kadowaki S, Muro K, Horio Y, Yoshida T, Oze I, Kajita M, Mizutani A.
    Asia Pac J Clin Oncol; 2016 Sep 01; 12(3):254-8. PubMed ID: 27030364
    [Abstract] [Full Text] [Related]

  • 6. A double-blind randomized Phase II study of olanzapine 10 mg versus 5 mg for emesis induced by highly emetogenic chemotherapy.
    Nagashima K, Iwasa S, Yanai T, Hashimoto H, Suzuki K, Ohyanagi F, Shimada Y, Yamamoto N.
    Jpn J Clin Oncol; 2015 Feb 01; 45(2):229-31. PubMed ID: 25398581
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Combination of palonosetron, aprepitant, and dexamethasone as primary antiemetic prophylaxis for cisplatin-based chemotherapy.
    Yang CK, Wu CE, Liaw CC.
    Biomed J; 2016 Feb 01; 39(1):60-6. PubMed ID: 27105599
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.
    Roila F, Ruggeri B, Ballatori E, Fatigoni S, Caserta C, Licitra L, Mirabile A, Ionta MT, Massidda B, Cavanna L, Palladino MA, Tocci A, Fava S, Colantonio I, Angelelli L, Ciuffreda L, Fasola G, Zerilli F.
    Ann Oncol; 2015 Jun 01; 26(6):1248-1253. PubMed ID: 25743855
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC).
    Karthaus M, Tibor C, Lorusso V, Singh-Arora R, Filippov A, Rizzi G, Borroni ME, Rossi G, Grunberg SM.
    Support Care Cancer; 2015 Oct 01; 23(10):2917-23. PubMed ID: 25724407
    [Abstract] [Full Text] [Related]

  • 16. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study.
    Navari RM, Einhorn LH, Passik SD, Loehrer PJ, Johnson C, Mayer ML, McClean J, Vinson J, Pletcher W.
    Support Care Cancer; 2005 Jul 01; 13(7):529-34. PubMed ID: 15700131
    [Abstract] [Full Text] [Related]

  • 17. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF, Liang Y, Zhou NN, Zhang DS, Wu HY.
    Intern Med J; 2013 Jan 01; 43(1):73-6. PubMed ID: 22141732
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.